About Bioventus Inc
Ticker
info
BVS
Trading on
info
NASDAQ
ISIN
info
US09075A1088
Industry
info
Medical Devices
Sector
info
Healthcare
CEO
info
-
Headquarters
info
4721 Emperor Boulevard, Durham, NC, United States, 27703
Employees
info
930
Website
info
bioventus.com
Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company's product portfolio includes pain treatments, which comprises of various intra-articular and hyaluronic acid injections, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain. Its surgical solutions comprise ultrasonic products offers precision bone resection for patients with degenerative spine conditions and spinal deformities, as well as enables precision ultrasonic neuro and general surgery to address brain tumors and pathologies of the liver and other organs; bone graft substitutes, a portfolio includes various products that facilitate optimal bone fusion. The company's product includes, nexus, an ultrasonic surgical system, an ultrasonic surgical platform; BoneScalpel, a surgical solution enabling precise cuts in hard tissue; SonaStar system, a precise ablation and removal of soft tissue; SonaStar Elite, a handpiece and accessories; SonicOne, an ultrasonic cleansing and debridement system; Osteoamp, an allograft-derived bone graft for orthopedic, neurosurgical and reconstructive bone grafting procedures; Signafuse bone graft; Purebone, a natural osteoconductive scaffold; and Reficio demineralized bone matrix. The company's restorative therapies, which includes minimally invasive fracture treatments and rehabilitation products. Its products include Exogen, an ultrasound bone stimulation system; and Talisman pulse generator and receiver for peripheral nerve stimulation. Bioventus Inc. was founded in 2011 and is headquartered in Durham, North Carolina.
Metrics
BasicAdvanced
Market cap
info
$495M
P/E ratio
info
-
EPS
info
-$0.52
Dividend Yield
info
0.00%
Beta
info
0.92
Forward P/E ratio
info
11.34
EBIDTA
info
$59M
Ex dividend date
info
-
Price & volume
Market cap
info
$495M
Average daily volume
info
0.3M
90-day return
info
-
30-day return
info
-
7-day return
info
-
Dividends
Dividend per share
info
$0.00
Dividend yield
info
0.00%
Forward dividend per share
info
$0.00
Forward dividend yield
info
0.00%
Payout ratio
info
0.00%
Valuation
P/E ratio
info
0
Forward P/E
info
11.34
PEG ratio
info
2.14
Trailing P/E
info
0
Price to sales
info
0.86
Price to book
info
3.35
Earnings
EPS
info
-$0.52
EPS estimate (current quarter)
info
$0.09
EPS estimate (next quarter)
info
$0.06
EBITDA
info
$59M
Revenues (TTM)
info
$573M
Revenues per share (TTM)
info
$8.88
Technicals
Beta
info
0.92
52-week High
info
$14.38
52-week Low
info
$3.90
50-day moving average
info
$9.71
200-day moving average
info
$10.01
Short ratio
info
1.83
Short %
info
1.62%
Management effectiveness
ROE (TTM)
info
21.55%
ROA (TTM)
info
3.24%
Profit margin
info
5.85%
Gross profit margin
info
$388M
Operating margin
info
7.23%
Growth
Quarterly earnings growth (YoY)
info
0.00%
Quarterly revenue growth (YoY)
info
13.50%
Share stats
Outstanding Shares
info
66.2M
Float
info
34.4M
Insiders %
info
11.47%
Institutions %
info
69.81%
Analyst Insights & forecasts
info

67% Buy

33% Hold

0% Sell

Based on information from 3 analysts.

Average price target

info
$15.00
Earnings per share (EPS) forecast
windowbar_chart_4_bars
Actual
info
Expected
info
Surprise
info
$0.07
-$0.07
200.00%
Q1 • 24Beat
$0.19
$0.07
171.43%
Q2 • 24Beat
$0.06
$0.03
100.00%
Q3 • 24Beat
$0.15
$0.09
76.47%
Q4 • 24Current
QuarterlyAnnual
Financial Performance
windowbar_chart_4_bars
Income StatementBalance SheetCash Flow
windowbar_chart_4_bars
Revenue
info
Net income
info
Profit margin
info
$139M
$-4.8M
3.47%
Q3 • 24
$154M
$-0.2M
0.10%
Q4 • 24
10.56%
96.77%
97.08%
QoQ growth
QuarterlyAnnual
Totals assets
info
Total liabilities
info
Debt to assets
info
$769M
$583M
75.72%
Q3 • 24
$728M
$542M
74.50%
Q4 • 24
5.40%
6.92%
1.61%
QoQ growth
QuarterlyAnnual
Operating
info
Investing
info
Financing
info
Free cash flow
info
$10.3M
$-0.1M
$0.4M
$10.3M
Q3 • 24
$19.3M
$24.1M
$-42.9M
$18.7M
Q4 • 24
87.30%
37,762.50%
11,938.40%
82.87%
QoQ growth
QuarterlyAnnual

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Bioventus Inc share?
Collapse

Bioventus Inc shares are currently traded for undefined per share.

How many shares does Bioventus Inc have?
Collapse

Bioventus Inc currently has 66.2M shares.

Does Bioventus Inc pay dividends?
Collapse

No, Bioventus Inc doesn't pay dividends.

What is Bioventus Inc 52 week high?
Collapse

Bioventus Inc 52 week high is $14.38.

What is Bioventus Inc 52 week low?
Collapse

Bioventus Inc 52 week low is $3.90.

What is the 200-day moving average of Bioventus Inc?
Collapse

Bioventus Inc 200-day moving average is $10.01.

Who is Bioventus Inc CEO?
Collapse

The CEO of Bioventus Inc is -.

How many employees Bioventus Inc has?
Collapse

Bioventus Inc has 930 employees.

What is the market cap of Bioventus Inc?
Collapse

The market cap of Bioventus Inc is $495M.

What is the P/E of Bioventus Inc?
Collapse

The current P/E of Bioventus Inc is null.

What is the EPS of Bioventus Inc?
Collapse

The EPS of Bioventus Inc is -$0.52.

What is the PEG Ratio of Bioventus Inc?
Collapse

The PEG Ratio of Bioventus Inc is 2.14.

What do analysts say about Bioventus Inc?
Collapse

According to the analysts Bioventus Inc is considered a buy.